WEBVTT 1 00:00:00.088 --> 00:00:02.270 This podcast is created by Coelis. 2 00:00:04.011 --> 00:00:05.152 In my vision of the future, 3 00:00:05.172 --> 00:00:05.732 in my dream, 4 00:00:05.833 --> 00:00:11.777 I foresee the integration of several advanced imaging technologies such as multi-parametric MRI, 5 00:00:12.278 --> 00:00:14.459 PSM-APET and micro-ultrasound. 6 00:00:24.224 --> 00:00:26.285 Hello and welcome to Prostatalk. 7 00:00:26.805 --> 00:00:32.749 Get ready to embark on a fascinating journey into the future of prostate cancer screening. 8 00:00:33.269 --> 00:00:33.749 Trust me, 9 00:00:34.029 --> 00:00:37.551 it's gonna be to be more exciting than a sci-fi movie. 10 00:00:38.432 --> 00:00:38.792 Today, 11 00:00:39.072 --> 00:00:46.036 we are diving into the lightest and greatest in prostate cancer diagnoses techniques with our Belgium guest, 12 00:00:46.196 --> 00:00:46.536 Dr. 13 00:00:46.856 --> 00:00:47.457 Romain Diamant. 14 00:00:48.337 --> 00:00:53.800 We will explore the dynamic duo of cutting-edge technologies and skilled urologists. 15 00:00:54.124 --> 00:00:55.965 Think of it as Batman and Robin, 16 00:00:56.385 --> 00:00:58.885 but with doctor's coats and high-tech machines. 17 00:00:59.586 --> 00:01:06.768 We'll also take a peek into the crystal ball to see how this innovation will evolve in the coming years. 18 00:01:07.248 --> 00:01:08.128 Spoiler alert, 19 00:01:08.228 --> 00:01:09.268 the future looks bright! 20 00:01:09.908 --> 00:01:10.949 So sit back, 21 00:01:11.369 --> 00:01:16.330 relax and let's talk about the amazing streets we are making in prostate health. 22 00:01:16.810 --> 00:01:19.811 Because when it comes to early detection and treatment, 23 00:01:20.171 --> 00:01:22.612 we are definitely not kidding around. 24 00:01:23.048 --> 00:01:24.830 Stay tuned and let's get started. 25 00:01:26.751 --> 00:01:27.312 Good morning, 26 00:01:27.392 --> 00:01:27.652 Dr. 27 00:01:27.692 --> 00:01:28.012 Diamant. 28 00:01:28.533 --> 00:01:31.255 We are really pleased to welcome you to our podcast, 29 00:01:31.395 --> 00:01:32.076 Prostatalk. 30 00:01:32.716 --> 00:01:33.397 How are you today? 31 00:01:34.177 --> 00:01:34.598 I am well, 32 00:01:34.698 --> 00:01:35.038 thank you, 33 00:01:35.198 --> 00:01:36.439 and happy to be here with you. 34 00:01:37.040 --> 00:01:38.401 Before to start this interview, 35 00:01:38.821 --> 00:01:40.723 I would like to know who is Dr. 36 00:01:40.763 --> 00:01:41.063 Diamant. 37 00:01:41.403 --> 00:01:43.665 Could you please tell us a bit about yourself? 38 00:01:44.106 --> 00:01:45.367 So I am Romain Diamant, 39 00:01:45.587 --> 00:01:49.190 urologist and associate professor at the Jules Bourdais Institute, 40 00:01:49.270 --> 00:01:51.452 a comprehensive cancer center in Belgium. 41 00:01:52.016 --> 00:01:53.317 since 2020. 42 00:01:54.077 --> 00:02:03.062 My specialities include urologic oncology and robotic surgery with a research focus on MRI targeted biopsy and prostate cancer diagnostic and treatment. 43 00:02:03.442 --> 00:02:16.409 I became a fellow of the European Board of Urology in 2021 and completed my PhD in 2023 which focused on MRI targeted biopsy and prostate cancer risk assessment. 44 00:02:16.849 --> 00:02:21.272 This work was recently rewarded by the Royal Society of Medicine which is 45 00:02:21.636 --> 00:02:23.316 A very good news for me and for my team. 46 00:02:23.597 --> 00:02:26.777 I treat patients with prostate cancer and bladder cancer. 47 00:02:27.078 --> 00:02:30.799 I perform robotic-assisted radical prostatectomies and cystectomies, 48 00:02:31.259 --> 00:02:34.780 do transrectal and transpirinal MRI-targeted biopsy, 49 00:02:35.100 --> 00:02:37.841 supervise clinical research on prostate cancer, 50 00:02:38.041 --> 00:02:41.422 and mentor young fellows in clinical practice and research. 51 00:02:42.262 --> 00:02:47.223 I also want to take the opportunity to congratulate you on receiving the prestigious 52 00:02:47.563 --> 00:02:49.384 Henri Fauconnier and Jeanne-Marie François 53 00:02:49.684 --> 00:02:56.008 academic award from the Royal Academy of Medicine of Belgium just a few weeks ago at the time of this interview. 54 00:02:56.408 --> 00:02:57.228 For our listeners, 55 00:02:57.308 --> 00:03:01.170 this award recognizes work aimed at cancer treatment and, 56 00:03:01.330 --> 00:03:01.791 in a way, 57 00:03:02.171 --> 00:03:05.553 marked the culmination of your PhD in medical sciences. 58 00:03:05.833 --> 00:03:07.614 Could you please tell us more about this award, 59 00:03:08.014 --> 00:03:12.537 what it means to you and especially how it serves as a springboard for your research? 60 00:03:13.657 --> 00:03:18.420 So thank you and this reward is here to reward 61 00:03:19.044 --> 00:03:28.091 The best work in cancer and it gives us the opportunity to have more fun and more legitimacy to do more research in the future with my team. 62 00:03:28.232 --> 00:03:30.553 So it's a very good news for us and for the patient, 63 00:03:30.634 --> 00:03:30.974 obviously. 64 00:03:31.774 --> 00:03:32.195 Congrats. 65 00:03:32.495 --> 00:03:36.778 Could you explain to us what is the landscape of the prostate cancer in Belgium? 66 00:03:37.259 --> 00:03:39.281 Do you have any reimbursements, 67 00:03:39.781 --> 00:03:41.282 specific screening plans? 68 00:03:42.263 --> 00:03:45.365 So prostate cancer is a significant health issue in Belgium, 69 00:03:45.506 --> 00:03:48.188 being the most commonly diagnosed cancer among men. 70 00:03:48.724 --> 00:03:53.486 with an incidence of more than 11,000 new cases in 2021, 71 00:03:54.046 --> 00:03:55.607 surpassing even breast cancer. 72 00:03:55.867 --> 00:03:56.447 In Belgium, 73 00:03:56.567 --> 00:04:01.489 the ILS-Care system provides reimbursement for many aspects of prostate cancer care. 74 00:04:01.589 --> 00:04:04.250 This includes obviously tests like PSA, 75 00:04:04.711 --> 00:04:09.553 but only for screening in case of positive family history and post-treatment follow-up. 76 00:04:10.113 --> 00:04:10.833 In other cases, 77 00:04:11.053 --> 00:04:13.354 the cost of PSA testing is approximately 78 00:04:13.694 --> 00:04:14.595 11 euros. 79 00:04:14.635 --> 00:04:17.556 Reimbursements also cover multi-parametric MRI 80 00:04:17.736 --> 00:04:21.978 and prostate biopsy but there is no specific nomenclature for targeted biopsy. 81 00:04:22.479 --> 00:04:26.581 Viro-treatment options such as surgery and radiation therapy are also reimbursed. 82 00:04:26.861 --> 00:04:27.502 Unfortunately, 83 00:04:27.842 --> 00:04:30.964 Belgium does not have a national prostate cancer screening program. 84 00:04:31.244 --> 00:04:31.724 However, 85 00:04:32.364 --> 00:04:38.528 opportunistic screening is very common where PSA testing is performed during routine health check-ups for men, 86 00:04:39.108 --> 00:04:45.572 particularly those over the age of 50 or younger in case of genetic mutation or African origin. 87 00:04:45.752 --> 00:04:55.649 We have also dedicated training structures such as the Cancer Prevention and Screening Center at Jules Baudet Institute that offer a cancer risk assessment service for all men. 88 00:04:57.091 --> 00:04:58.474 How do you take part of it? 89 00:04:59.106 --> 00:04:59.346 I mean, 90 00:04:59.426 --> 00:05:02.428 how do you push to your own way, 91 00:05:02.868 --> 00:05:07.331 like a specific reimbursement or specific new screening plan, 92 00:05:07.371 --> 00:05:07.871 for example? 93 00:05:08.392 --> 00:05:08.532 Yes, 94 00:05:08.572 --> 00:05:08.952 obviously, 95 00:05:09.933 --> 00:05:11.093 I deal with screening, 96 00:05:11.213 --> 00:05:12.954 treatment and follow-up for my patients. 97 00:05:13.555 --> 00:05:19.098 Our department of urology is deeply involved in advocating for the establishment of a new nomenclature, 98 00:05:19.598 --> 00:05:22.580 especially to secure reimbursement for targeted biopsy. 99 00:05:23.421 --> 00:05:23.901 Additionally, 100 00:05:24.501 --> 00:05:25.342 we are dedicated 101 00:05:25.422 --> 00:05:31.324 to promoting the implementation of a national screening program for prostate cancer in Belgium and across Europe. 102 00:05:31.864 --> 00:05:32.424 This morning, 103 00:05:32.464 --> 00:05:35.365 I had the chance to assist to a focal therapy session. 104 00:05:35.725 --> 00:05:36.985 It was a TMA procedure, 105 00:05:37.025 --> 00:05:38.466 a targeted microevabulation. 106 00:05:38.906 --> 00:05:41.306 Could you please explain to our listeners what is it? 107 00:05:41.787 --> 00:05:47.248 So TMA used a microwave energy to eat and destroy cancer cells in the prostate gland. 108 00:05:47.528 --> 00:05:54.250 A dedicated probe is placed transrectally or transparently into the prostate under ultrasound guidance. 109 00:05:54.706 --> 00:05:59.587 using 3D MRI ultrasound fusion technology combined with real-time prostate tracking. 110 00:05:59.868 --> 00:06:07.430 This approach precisely targets and kills MRI lesion and prostate cancer cells while minimizing damage to LCA tissue. 111 00:06:07.930 --> 00:06:14.932 One of the significant advantages of this thermoablative technique is that the procedure is performed under mild sedation, 112 00:06:15.772 --> 00:06:19.733 allowing patients to go home the same day and recover very quickly. 113 00:06:20.173 --> 00:06:20.653 Additionally, 114 00:06:20.894 --> 00:06:22.174 if treatment failure occurs, 115 00:06:22.758 --> 00:06:26.120 Radical treatment can still be performed afterward without difficulty, 116 00:06:26.300 --> 00:06:33.845 for example for the dissection of the neurovascular bundle as demonstrated in our recent ABLET and RESECT study Faustine 1b. 117 00:06:34.385 --> 00:06:48.473 They are very promising results with TMA and we are very involved in the recent multicentric study VIOLETS evaluating the treatment's efficacy including a biopsy control one year after treating isolated grade 2 prostate cancer. 118 00:06:48.733 --> 00:06:49.554 We have observed 119 00:06:49.794 --> 00:06:53.416 a real enthusiasm among patients benefiting from this treatment. 120 00:06:53.936 --> 00:06:57.979 This enthusiasm has made our center one of the most active in studio recruitments, 121 00:06:58.519 --> 00:07:01.420 allowing us to include more patients than initially planned. 122 00:07:02.061 --> 00:07:02.221 Wow, 123 00:07:02.461 --> 00:07:02.861 well done. 124 00:07:03.462 --> 00:07:04.702 Thanks for these precisions. 125 00:07:05.203 --> 00:07:05.443 Dr. 126 00:07:05.483 --> 00:07:05.843 Diamant, 127 00:07:06.123 --> 00:07:06.263 well, 128 00:07:06.303 --> 00:07:07.644 when I was preparing this interview, 129 00:07:07.684 --> 00:07:13.207 I have noticed that you do a lot of researches and you mentioned your recent research and publication about TMA, 130 00:07:13.307 --> 00:07:13.927 for example, 131 00:07:14.288 --> 00:07:16.469 but also about many other topics, 132 00:07:16.829 --> 00:07:17.749 all in prostate field, 133 00:07:18.110 --> 00:07:18.530 obviously. 134 00:07:18.954 --> 00:07:23.438 I assume that you have a particular interest in innovation and disruptive technique, 135 00:07:23.678 --> 00:07:23.918 right? 136 00:07:24.478 --> 00:07:24.979 Yes indeed, 137 00:07:25.179 --> 00:07:29.322 my involvement in ClinCa research is driven by two main objectives. 138 00:07:29.682 --> 00:07:30.103 Firstly, 139 00:07:30.503 --> 00:07:35.687 I aim to respond to the daily questions and challenges that urologists have in their daily practice. 140 00:07:36.107 --> 00:07:36.528 Recently, 141 00:07:36.648 --> 00:07:40.111 my team has published several papers on optimal biopsy templates. 142 00:07:40.391 --> 00:07:44.314 These include for example the exact area to target within the MRI lesion, 143 00:07:44.662 --> 00:07:47.884 determining the optimal number of targeted biopsy cores, 144 00:07:48.104 --> 00:07:51.066 evaluating the added value of sampling the periliginal area, 145 00:07:51.407 --> 00:07:55.609 and assessing the role of systematic biopsy based on the location of MRI lesion. 146 00:07:55.910 --> 00:07:56.410 Additionally, 147 00:07:56.710 --> 00:08:05.136 we have published numerous papers on using biopsy information in multivariate models to predict outcomes such as the risk of lymph node invasion, 148 00:08:05.476 --> 00:08:07.497 the risk of extraprostatic extension, 149 00:08:07.978 --> 00:08:11.260 and the risk of unfavorable disease in active surveillance cores. 150 00:08:11.800 --> 00:08:14.202 These research efforts were made 151 00:08:14.322 --> 00:08:19.586 possible by a large network of friends and colleagues among several European centers, 152 00:08:19.786 --> 00:08:21.207 both academic and private, 153 00:08:21.627 --> 00:08:22.848 over several years. 154 00:08:23.129 --> 00:08:23.649 To date, 155 00:08:24.249 --> 00:08:29.794 approximately 27 European centers have participated in at least one of our studies, 156 00:08:30.354 --> 00:08:40.882 and we have collected data from over 5,000 patients diagnosed by MRI-targeted biopsy and approximately 3,000 who underwent radical prostatectomies. 157 00:08:41.598 --> 00:08:43.459 And stop me if I'm wrong, 158 00:08:43.499 --> 00:08:43.759 Dr. 159 00:08:43.779 --> 00:08:44.059 Diamant, 160 00:08:44.360 --> 00:08:51.964 but your recent study on prostate cancer diagnosis examined the impact of transitioning from transrectal to transperineal biopsies, 161 00:08:52.344 --> 00:08:56.847 focusing on their effectiveness and clinically significant concern detection rate. 162 00:08:57.547 --> 00:09:06.212 This somewhat goes against the grain of those advocating exclusively for transperineal biopsy and abandoning the transrectal approach. 163 00:09:06.633 --> 00:09:08.974 Could you present the main findings of your research? 164 00:09:09.274 --> 00:09:12.435 and their implications for the future diagnosis practice. 165 00:09:13.555 --> 00:09:24.418 So we did research on a large cohort of patients in Europe and we found that a transparent approach gives us better accuracy and detection rate for prostate cancer. 166 00:09:25.058 --> 00:09:25.458 Obviously, 167 00:09:25.558 --> 00:09:31.320 we need level 1 evidence with randomized trials and we have no data on that actually. 168 00:09:31.840 --> 00:09:39.022 The recent data show that maybe the risk of complication and more particularly the infection one is that the risk of complication is higher 169 00:09:39.146 --> 00:09:41.288 It's not very different between the two approaches, 170 00:09:41.808 --> 00:09:43.130 but at one condition, 171 00:09:43.690 --> 00:09:48.675 that transperinale biopsy is no longer associated with antibiotics. 172 00:09:48.815 --> 00:09:53.499 So I think that in terms of antibiotics problem and resistance, 173 00:09:53.619 --> 00:09:55.581 it's better to switch to transperinale. 174 00:09:55.621 --> 00:09:56.702 But in terms of detection, 175 00:09:56.762 --> 00:10:01.967 we have some data that shows that maybe transperinale is associated with better outcome, 176 00:10:02.107 --> 00:10:04.649 but we need more 11.1 evidence. 177 00:10:05.517 --> 00:10:05.737 Okay, 178 00:10:05.757 --> 00:10:06.057 good. 179 00:10:06.758 --> 00:10:08.619 That brings me to my next question. 180 00:10:08.959 --> 00:10:12.981 How do you see the diagnostic pathway of prostate cancer in the next few years? 181 00:10:13.742 --> 00:10:15.082 Over the next few years, 182 00:10:15.162 --> 00:10:18.604 we can expect significant advancements in diagnostic prostate cancer, 183 00:10:18.684 --> 00:10:20.425 but this is a very complex issue. 184 00:10:21.086 --> 00:10:21.486 Firstly, 185 00:10:22.326 --> 00:10:24.968 better imaging technique will play a crucial role. 186 00:10:25.268 --> 00:10:30.191 Improvements in multi-parametric MRI protocols will offer more precise imaging, 187 00:10:30.391 --> 00:10:33.833 helping physicians better identify and target biopsy areas. 188 00:10:34.373 --> 00:10:41.695 This improves image quality and for example we have the PQAL score that gives us an information regarding the image quality, 189 00:10:42.515 --> 00:10:58.200 the radiologist expertise with precise criteria to define how a radiologist is considered as an expert and the biopsy procedure itself depending on the expertise of the physician who performs the biopsy and the biopsy platform obviously. 190 00:10:59.060 --> 00:11:00.861 Additionally combining PSMF 191 00:11:00.981 --> 00:11:04.944 PET and MRI is expected to become a standard tool in my opinion. 192 00:11:05.244 --> 00:11:09.527 This approach will help to detect and locate prostate cancer more accurately, 193 00:11:10.187 --> 00:11:14.110 identifying significant cancer and reducing unnecessary biopsy. 194 00:11:14.851 --> 00:11:19.194 We will also have better ultrasound probes with improved image resolution, 195 00:11:19.474 --> 00:11:23.016 particularly with the generalization of micro-ultrasound platforms. 196 00:11:23.957 --> 00:11:24.377 Secondly, 197 00:11:24.597 --> 00:11:29.661 biomarkers and liquid biopsy will revolutionize early detection and monitoring. 198 00:11:30.173 --> 00:11:36.855 We will see new blood and urine tests based on genomic biomarkers that can detect prostate cancer in high accuracy. 199 00:11:37.815 --> 00:11:38.215 Finally, 200 00:11:38.775 --> 00:11:42.857 artificial intelligence will significantly impact diagnostic pathway. 201 00:11:43.737 --> 00:11:48.638 AI-driven imaging analysis will improve the interpretation of imaging studies, 202 00:11:48.938 --> 00:11:51.699 making diagnoses more accurate and consistent. 203 00:11:52.439 --> 00:11:58.121 I expect that prostate and suspicious lesion will be automatically delineated for biopsy. 204 00:11:58.789 --> 00:12:05.475 Predictive models developed through AI will assess individual patient risk using a combination of clinical, 205 00:12:05.955 --> 00:12:07.817 imaging and molecular data, 206 00:12:08.317 --> 00:12:12.220 leading to more personalized and precise diagnostic pathways. 207 00:12:12.921 --> 00:12:14.882 Does that mean that PSA tests, 208 00:12:14.943 --> 00:12:16.464 high-quality MRI or, 209 00:12:17.124 --> 00:12:17.485 I don't know, 210 00:12:17.505 --> 00:12:20.928 even a urine exam will be enough to diagnose prostate cancer? 211 00:12:21.428 --> 00:12:21.988 Not necessarily. 212 00:12:22.189 --> 00:12:23.530 I think there's many, 213 00:12:23.610 --> 00:12:27.173 many new technologies that will be there in the diagnostic pathway. 214 00:12:27.573 --> 00:12:32.777 and the combination of all this data will improve and personalize the diagnostic pathway. 215 00:12:33.818 --> 00:12:34.399 Interesting. 216 00:12:34.879 --> 00:12:37.521 So taking into account all this information, 217 00:12:37.722 --> 00:12:38.062 for you, 218 00:12:38.743 --> 00:12:40.444 what will be the biopsy of the future? 219 00:12:41.044 --> 00:12:42.486 So in my vision of the future, 220 00:12:42.486 --> 00:12:43.066 in my dream, 221 00:12:43.146 --> 00:12:46.689 I foresee the integration of several advanced imaging technologies, 222 00:12:47.370 --> 00:12:49.111 such as multi-parametric MRI, 223 00:12:49.572 --> 00:12:50.332 PSM-APET, 224 00:12:50.512 --> 00:12:51.774 and micro-ultrasound. 225 00:12:52.094 --> 00:12:52.975 These modalities, 226 00:12:53.435 --> 00:12:55.637 each offering unique strengths in detecting 227 00:12:55.937 --> 00:12:59.220 prostate cancer lesion will work synergistically. 228 00:12:59.821 --> 00:13:05.366 Artificial intelligence will automate detection and delineation of the prostate with suspicious lesion. 229 00:13:06.047 --> 00:13:14.515 Real-time evaluation of biopsy trajectory will further enhance accuracy with systems signaling any deviation for immediate correction. 230 00:13:15.036 --> 00:13:17.879 I believe systematic biopsy will no longer be necessary, 231 00:13:18.299 --> 00:13:20.061 resulting in shorter procedures. 232 00:13:20.997 --> 00:13:26.759 How soon do you think these biopsies of the future will be available to doctors and beneficial for patients? 233 00:13:27.239 --> 00:13:28.939 The technologies of MRI, 234 00:13:29.059 --> 00:13:33.321 PSMA PET and micro-ultrasound are already available individually. 235 00:13:33.681 --> 00:13:36.962 Artificial intelligence has shown promising results, 236 00:13:37.202 --> 00:13:44.364 such as a recent study by Saha in the Lancet Oncology demonstrating improved diagnostic abilities compared to radiologists. 237 00:13:45.104 --> 00:13:45.504 However, 238 00:13:46.204 --> 00:13:48.165 integrating these technologies into a clinical trial is not possible. 239 00:13:48.225 --> 00:13:54.727 cohesive system present a significant challenge in a competitive market driven by financial interest. 240 00:13:55.607 --> 00:14:03.150 Achieving the biopsy of the future will require open source data and technologies along with extensive collaboration and dedication. 241 00:14:03.910 --> 00:14:11.373 I am hopeful that with enough motivation and effort we can make these integrated technologies accessible within the next decade. 242 00:14:11.773 --> 00:14:12.133 I hope. 243 00:14:12.735 --> 00:14:15.876 So I want to jump to a topic that you mentioned previously. 244 00:14:16.157 --> 00:14:18.257 In a world where artificial intelligence, 245 00:14:18.398 --> 00:14:22.399 robotic surgery or any technologies are taking more and more space, 246 00:14:22.739 --> 00:14:28.062 how do you see the collaboration between physicians and especially urologists and technology in the future? 247 00:14:28.602 --> 00:14:31.743 AI will significantly enhance urologist abilities. 248 00:14:32.084 --> 00:14:39.627 It will help us interpret imaging studies more efficiently and create personalized treatment plans for each patient. 249 00:14:39.943 --> 00:14:40.423 Given that, 250 00:14:40.623 --> 00:14:42.564 future cooperation will be fundamental. 251 00:14:42.924 --> 00:14:45.125 Urologists will work closely with engineers, 252 00:14:45.705 --> 00:14:46.546 data scientists, 253 00:14:46.586 --> 00:14:51.548 and software developers to innovate and refine technologies specific to urological cares. 254 00:14:51.868 --> 00:14:53.529 Continuous education will be crucial. 255 00:14:53.889 --> 00:15:02.532 Urologists must stay updated with the latest technology and undergo specialized training to integrate this technology and innovation effectively. 256 00:15:03.233 --> 00:15:04.333 In the episode 3, 257 00:15:04.493 --> 00:15:05.193 we asked Dr. 258 00:15:05.233 --> 00:15:06.594 Michael Lees from San Antonio, 259 00:15:06.694 --> 00:15:07.114 Texas, 260 00:15:07.454 --> 00:15:09.035 about his opinion about AI. 261 00:15:09.543 --> 00:15:09.963 For him, 262 00:15:10.143 --> 00:15:11.864 AI is very interesting and it's going to be, 263 00:15:12.504 --> 00:15:12.764 I mean, 264 00:15:12.964 --> 00:15:15.805 like a big shift and it's going to change medicine for sure. 265 00:15:16.285 --> 00:15:17.085 Are you OK with that? 266 00:15:17.646 --> 00:15:32.070 I totally agree with Assumption that AI will be a real revolution in our daily practice in terms of the prediction of prostate cancer and for the daily practice with image analysis and treatment solutions. 267 00:15:32.130 --> 00:15:32.250 So, 268 00:15:32.390 --> 00:15:32.650 yes, 269 00:15:32.690 --> 00:15:34.951 it will be a big shift in our practice. 270 00:15:35.547 --> 00:15:41.489 And how does this progress and changes are impacting your daily work and how this will impact on patients? 271 00:15:41.950 --> 00:15:43.430 As a neurologist and researcher, 272 00:15:43.610 --> 00:15:47.872 I've seen how new technologies are becoming more complex to adopt and understand. 273 00:15:48.572 --> 00:15:51.313 While we develop new ways to diagnose and treat patients, 274 00:15:51.374 --> 00:15:54.475 it's crucial for us to work closely with engineers. 275 00:15:55.095 --> 00:16:02.658 Our main challenge is to create straightforward and easy-to-use interfaces that everyone can use to benefit from our research. 276 00:16:03.678 --> 00:16:04.719 Do you have any tips? 277 00:16:04.939 --> 00:16:12.165 our advice is to give to our listeners who don't know how to handle the progresses or the one who fears about technology. 278 00:16:12.665 --> 00:16:13.486 As I mentioned, 279 00:16:13.826 --> 00:16:15.848 developing these technologies is complex, 280 00:16:16.248 --> 00:16:19.451 but not everyone needs to understand all the details, 281 00:16:19.551 --> 00:16:19.951 I think. 282 00:16:20.512 --> 00:16:26.116 What matters most is how to reuse them practically and they add real added value in daily practice. 283 00:16:26.256 --> 00:16:29.099 The goal of all this advancement is simple, 284 00:16:29.619 --> 00:16:34.363 to improve patient care and quality of life by reducing over-diagnostic and over-treatment. 285 00:16:34.911 --> 00:16:36.653 There are more and more training courses, 286 00:16:36.933 --> 00:16:41.476 especially during international meetings such as the EAU or AUI congresses, 287 00:16:41.957 --> 00:16:43.999 where experts share their knowledge. 288 00:16:44.619 --> 00:16:47.281 It's normal to feel a bit worried about this change, 289 00:16:47.341 --> 00:16:50.784 but humans will be still crucial in the diagnostic and treatment process. 290 00:16:51.625 --> 00:16:51.925 Thank you, 291 00:16:51.925 --> 00:16:52.185 Dr. 292 00:16:52.205 --> 00:16:52.486 Diamant. 293 00:16:52.966 --> 00:16:54.007 Talking about future, 294 00:16:54.087 --> 00:16:57.790 could you tell us what are you working on and what are your next plans? 295 00:16:57.910 --> 00:16:58.050 Well, 296 00:16:58.370 --> 00:17:00.452 my question is a bit leaning because 297 00:17:00.792 --> 00:17:03.895 I've heard that you want to establish a prostate clinic. 298 00:17:04.223 --> 00:17:04.783 Is that true? 299 00:17:05.343 --> 00:17:05.523 Yes, 300 00:17:05.523 --> 00:17:06.004 that's true. 301 00:17:06.124 --> 00:17:10.165 This is a project with our department and with our hospital, 302 00:17:10.225 --> 00:17:13.226 but we are just at the beginning of this project. 303 00:17:13.246 --> 00:17:15.166 So I will give you more detail in the future. 304 00:17:15.886 --> 00:17:18.627 And regarding the next research project, 305 00:17:19.287 --> 00:17:19.967 as I said, 306 00:17:20.047 --> 00:17:29.170 my main project focuses on evaluating the benefit of PSMH-PetMRI for patients with uncertain cancer risk and developing AI-based prediction models. 307 00:17:29.810 --> 00:17:31.791 We have a strong collaboration with... 308 00:17:33.403 --> 00:17:37.884 AI units at the University Health Network and CNA systems in Toronto, 309 00:17:38.464 --> 00:17:41.545 where we are actively working on several AI models. 310 00:17:41.965 --> 00:17:42.986 In my next research, 311 00:17:43.306 --> 00:17:48.387 I plan to improve surgical procedure for better evaluating prostate cancer detection during surgery, 312 00:17:48.967 --> 00:17:51.488 aiming to reduce the risk of positive margin. 313 00:17:51.508 --> 00:17:54.509 We are exploring new methods like rapid 314 00:17:54.989 --> 00:17:55.929 3D PET imaging, 315 00:17:56.009 --> 00:17:56.990 confocal microscopy, 316 00:17:57.330 --> 00:17:58.510 and fluorescence imaging. 317 00:17:58.850 --> 00:18:01.491 This is one of many projects we can... 318 00:18:02.315 --> 00:18:06.979 take part so I hope we'll have new response in the next day or years. 319 00:18:07.580 --> 00:18:07.800 Great, 320 00:18:07.840 --> 00:18:09.481 we can't wait to follow these projects. 321 00:18:10.082 --> 00:18:11.263 I have a last question, 322 00:18:11.363 --> 00:18:12.804 like a surprise question, 323 00:18:12.904 --> 00:18:13.885 sorry for that Dr. 324 00:18:13.925 --> 00:18:14.285 Diamant. 325 00:18:15.126 --> 00:18:16.707 What is your song of the moment? 326 00:18:18.069 --> 00:18:19.089 Very good question. 327 00:18:19.470 --> 00:18:20.511 I'm from France, 328 00:18:20.931 --> 00:18:24.994 as a French guy I like some French band like Justice. 329 00:18:25.355 --> 00:18:27.677 So the last one I heard every morning, 330 00:18:27.697 --> 00:18:30.139 the morning to have energy before working. 331 00:18:30.499 --> 00:18:32.140 is never under from justice. 332 00:18:32.621 --> 00:18:32.901 Okay, 333 00:18:33.321 --> 00:18:34.582 really good choice. 334 00:18:35.863 --> 00:18:38.686 Thanks again for your time and this precious information. 335 00:18:38.926 --> 00:18:41.128 We hope you enjoyed the exercise. 336 00:18:41.588 --> 00:18:47.933 And I give you the next invitation to few months few few years about your clinic projects. 337 00:18:48.414 --> 00:18:48.874 With pleasure. 338 00:18:49.094 --> 00:18:49.295 Thanks. 339 00:18:49.655 --> 00:18:50.015 Thank you. 340 00:18:50.035 --> 00:18:50.435 Bye bye. 341 00:18:50.456 --> 00:18:50.836 Thanks a lot. 342 00:18:52.057 --> 00:18:54.539 Huge thanks to our dedicated listeners. 343 00:18:54.999 --> 00:18:56.561 If you enjoyed the podcast, 344 00:18:56.761 --> 00:18:59.383 make sure to subscribe for more captivating content. 345 00:18:59.947 --> 00:19:01.874 Your support means the world. 346 00:19:03.568 --> 00:19:05.188 If you found this informative, 347 00:19:05.449 --> 00:19:06.369 quick favor please, 348 00:19:06.689 --> 00:19:07.989 drop up a 5-star review. 349 00:19:08.449 --> 00:19:12.811 Your feedback helps us grow and deliver quality insight. 350 00:19:12.811 --> 00:19:14.431 Have topics you'd love us to cover? 351 00:19:14.831 --> 00:19:18.232 Share your ideas in the comments or connect with us on social media. 352 00:19:18.832 --> 00:19:21.673 Your input guides the future of Pros.Talk. 353 00:19:22.173 --> 00:19:24.934 Thanks for being a crucial part of our community. 354 00:19:25.854 --> 00:19:27.475 For more urology insights, 355 00:19:27.815 --> 00:19:28.955 visit Collease.com. 356 00:19:29.375 --> 00:19:31.456 Stay tuned and see you next time.